Siemens Healthcare announced FDA approval of their MAGNETOM Prisma, a 3T MRI scanner.
Siemens Healthcare announced FDA approval of their MAGNETOM Prisma, a 3T MRI scanner designed to provide high spatial and temporal resolution, particularly in highly demanding applications.
The MAGNETOM Prisma features XR Gradients, which combine 80 milliTesla per meter with a 200T-per-meter-per-second slew rate to offer a configuration unavailable in any other commercial whole-body system. The system is designed to maintain precision throughout long, demanding applications such as functional MRI. The system’s first-to-market Diffusion Spectrum Imaging (DSI) acquisition enables the user to potentially resolve fine anatomical details of the brain such as crossing white-matter fibers, the company said.
MAGNETOM Prisma’s benchmark homogeneity and advanced shimming solutions allow for finer, more effective compensation of patient-induced field disturbances. The MAGNETOM Prisma has Siemens’ Dot (Day optimizing throughput) engines that enable consistency for research applications and clinical work, the company said. The Dot engine brings automation and reproducibility to investigations across subjects, time points, and institutions.
Siemens will offer onsite upgrades to the MAGNETOM Prisma to customers who have already installed the MAGNETOM Trio.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.